NASDAQ:HALO
Halozyme Therapeutics Stock News
$44.71
-0.680 (-1.50%)
At Close: May 17, 2024
7 Biotech Stocks With Key Catalysts Coming in July
06:15am, Monday, 27'th Jun 2022
Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on Inv
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
01:13pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
10:24am, Tuesday, 21'st Jun 2022
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
Halozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 09'th Jun 2022
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
08:30am, Wednesday, 08'th Jun 2022
SAN DIEGO , June 8, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present a
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
01:40pm, Wednesday, 25'th May 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt
04:15pm, Thursday, 19'th May 2022 Zacks Investment Research
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
01:35pm, Thursday, 19'th May 2022 Zacks Investment Research
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
11:17am, Thursday, 19'th May 2022
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Community Health (CYH) Boosts Obstetrics Care With Technology
02:44pm, Tuesday, 17'th May 2022 Zacks Investment Research
Community Health (CYH) employs PeriGen's technology to bring about enhanced obstetrics services and assure the safety of mothers as well as babies in the labor and delivery procedures.
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
01:40pm, Monday, 16'th May 2022 Zacks Investment Research
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
01:36pm, Wednesday, 11'th May 2022 Zacks Investment Research
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
11:17am, Wednesday, 11'th May 2022
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2022 Results - Earnings Call Transcript
10:14pm, Tuesday, 10'th May 2022
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Fina
